Oropharyngeal candidiasis outcomes in renal transplant recipients receiving nystatin versus no antifungal prophylaxis

Objective To compare the incidence of oropharyngeal candidiasis (OC), or thrush, in renal transplant recipients receiving nystatin versus no antifungal prophylaxis. Methods This was a single-center, retrospective, non-inferiority study adult (RTRs) who received for 30 days OC prophylaxis (nystatin group) therapy (No PPX group). The primary outcome within 3 months post-transplant. Secondary outcomes included time to occurrence and severity OC. pre-specified margin 10%. Results post-transplant among 257 RTRs 7.8% (10/128) No group 4.7% (6/129) group, risk difference 3.2% (95% CI, ?2.7% 9.1%, P = .04). median 7.5 (IQR 6.3-34.3 days) 9.5 5.3-30.5 (P .64). Esophageal observed 10% (1/10) with compared 16.7% (1/6) 1.00). All achieved symptom resolution fluconazole and/or nystatin. Two patients required readmission decreased oral intake, diagnosed treated during their hospital day. Conclusions In this retrospective RTRs, absence demonstrated 30-day at reducing transplant. may not be warranted after